LCM
BCTX

LuminArx Capital Management’s Briacell Therapeutics BCTX Stock Holding History

LuminArx Capital Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.6K Hold
15,000
– – 0.02% 83
2026
Q1 		$62.9K Buy
+15,000
New +$69.9K 0.05% 73

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

LuminArx Capital Management's BCTX Position: Q2 2026 in Review

LuminArx Capital Management held its Briacell Therapeutics (BCTX) position steady in Q2 2026 at 15,000 shares worth $48.6K. The position accounts for 0.02% of the portfolio, ranked #83.

LuminArx Capital Management first reported a position in BCTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $62.9K in Q1 2026. 19 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

  • LuminArx Capital Management held 15,000 shares of Briacell Therapeutics worth $48.6K as of Q2 2026.
  • LuminArx Capital Management left its Briacell Therapeutics share count unchanged in Q2 2026.
  • Briacell Therapeutics made up 0.02% of LuminArx Capital Management's portfolio in Q2 2026, its #83 holding.
  • LuminArx Capital Management first reported a position in Briacell Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • LuminArx Capital Management's Briacell Therapeutics position peaked at $62.9K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on LuminArx Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.